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Objective/Background: The aim of this work was to study the efficacy and safety of quercetin
and polyvinylpyrrolidone (QP) in the treatment of patients with newly diagnosed destruc-
tive pulmonary tuberculosis (TB) in comparison with standard antimycobacterial therapy.
Materials and methods: The study involved 124 patients aged between 20 years and 70 years
with newly diagnosed destructive pulmonary TB. Patients were allocated to two groups.
The first (control) group received standard antimycobacterial and pathogenetic therapy
and included 31 (25.0 ± 3.89%) patients. The second (main) group of patients received QP
therapy in addition to chemotherapy and included 93 (75.0 ± 3.89%) patients. All patients
received standard chemotherapy, consisting of oral isoniazid (0.3 g), rifampicin (0.6 g),
pyrazinamide (2 g), ethambutol (1.2 g), and/or an intramuscular injection of streptomycin
(1 g) with a dose reduction after the intensive phase of therapy. The anti-TB drugs were pro-
cured through the centralized national supply system in Ukraine. QP was used at a dose of
0.5 g in 100 mL 0.9% sodium chloride solution intravenously once per day for 10 days, start-
ing on admission to hospital.
Results: Intoxication symptoms in the second group were reduced after 1.33 ± 0.15 months,
whereas in the first group, intoxication symptoms were reduced following 2.64
± 0.20 months (p < 0.001). Moreover, respiratory symptom regression in the second group
was observed after 1.43 ± 0.30 months, whereas in the first group, it was after 2.33
± 0.30 months (p < 0.05). Bacillary excretion period evaluated within 3 months was reduced,
as it was shown by 97.67 ± 1.63% in the main group compared to 72.41 ± 8.45% (p < 0.05) in
the control group. In addition, the period of cavity healing was reduced to 2.86
± 0.15 months in the main group compared to 3.43 ± 0.20 months (p < 0.05) in the control
group. Residual radiological lung damage findings (mild or slight or even no signs) were
observed in 84 (90.32 ± 3.07%) patients in the main group versus 22 (70.97 ± 8.15%) patients
in the control group. Significant residual radiological lung damage findings were observed
in nine (9.68 ± 3.07%) patients in the main group and in nine (29.03 ± 8.15%) patients in thef Phthisiology and Pulmonology, Kharkiv National Medical University, 4 Nauky Avenue,
. Butov).
rican Society for Mycobacteriology.
Eﬃcacy and safety of quercetin and polyvinylpyrrolidone in treatment of patients with newly diag-
parison with standard antimycobacterial therapy. Int. J. Mycobacteriol. (2016), http://dx.doi.org/
2 I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y x x x ( 2 0 1 6 ) x x x –x x x
Please cite this article in press as: D Butov et al.
nosed destructive pulmonary tuberculosis in com
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Conclusion: Administration of QP combined with chemotherapy in patients with newly
diagnosed destructive pulmonary TB resulted in a rapid reduction in disease manifestation.Conflicts of interest
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